Brought to you by 
J&J is acquiring Centocor
Aug 1999
Executive Summary
Johnson & Johnson will acquire Centocor Inc. (monoclonal antibodies) for $4.9bn in stock (0.639 share of J&J for each Centocor share). Centocor's ReoPro, a platelet-inhibiting MAb, will complement the Palmaz-Schatz coronary stents sold by J&J's Cordis unit.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
J&J is acquiring Centocor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice